ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 5 6 Next >

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

February 20, 2025

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

February 14, 2025

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

February 12, 2025

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Present at Upcoming Investor Conferences

January 30, 2025

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

January 22, 2025

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

January 15, 2025

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 06, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

December 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

December 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

December 02, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

November 26, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

November 06, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

November 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

October 30, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

October 28, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

October 15, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Appoints Chris Degnan as Chief Financial Officer

October 09, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

October 02, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

September 16, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Present at Upcoming Investor Conferences

August 29, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 14, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

August 13, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

August 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

June 17, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

June 13, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 07, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024

June 06, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

June 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

June 03, 2024

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.